Similarly, the association between a lower risk of MACEs and the use of SGLT-2i was observed consistently among patients with hypertension and those using RAAS blockers, and in particular among patients with advanced CKD and those who were not receiving insulin or other OHAs or diuretics. Here, INS is linked to chronic kidney disease.